Avadel Pharma

Forecast & Rating10 analysts currently cover Avadel Pharma, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $20.94, about 3.2% downside from the current price of $21.64. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 19.6% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Avadel Pharma's outlook. Data as of Feb 3, 2026; for reference only and not investment advice.